A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment

Inclusion Criteria:

• Confirmed diagnosis of DMD able to be corrected by skipping Exon 51

• Body weight at least 18kg at Screening

• Performance of Upper Limb (PUL) 2.0 entry score of at least 4 at Screening (assessing upper limb function in ambulant and non-ambulant individuals with DMD)

Exclusion Criteria:

• Known history or presence of any clinically significant conditions that mayinterfere with study safety assessments

• Treatment with any gene replacement therapy for the treatment of DMD at any time

• Current or recent systemic infection within 2 weeks prior to Screening or infectionrequiring IV antibiotics within 4 weeks prior to Screening

• Recent surgery requiring anesthesia within 3 months prior to Screening or expectedsurgery requiring general anesthesia during the study